The International Forum for Generic Drugs was held in Shanghai on the 17th -18th November 2011. It was organised by the China Center for Pharmaceutical Industry Exchange (CCPIE) of the State Food and Drug Administration (SFDA) and coordinated by Stravecon Ltd. The main sponsors were Stravencon, Vermillion partners, Amerigen, WSGR and the EU China Trade Programme.

The forum was extremely well attended by over 300 delegates and senior officials from the SFDFA, CCMHPIE, WHO, USFDA, European Commission, MHRA, Health Canada and UKTI were invited as guest speakers.

The following topics were covered and copies of their presentations are available for download following registration.

1.  Increased Collaboration Catalyst for Regulatory Convergence
     Justina Molzon JD, USFDA, Associate Director of International Programs Center
     (A18-1400JM)

2.  The Regulation of Generic Drugs in Canada-Present & Future
      Andrew Adams, Director, Health Canada
      (A17-1010AA)

3.  EU moves to control Active Pharmaceutical Ingredients (API’s)
     Patrick Deboyser, Advisor to Director General of the Health & Consumers Directorate of EC
     (A17-1040PB)

4.  The Global Generics Market
     Matt Guagenty, Managing Principal, IMS China
     (A17-1125MG)

5.  M& A Opportunities for Chinese Pharmaceutical Companies in EU & USA
     Ed Radcliffe, Vermillion Partners
     (A11-1155ER)

6.  Pathway to Market Access - European Regulatory Requirements
     Gerald Heddell, Director of Inspection & Enforcement, MHRA UK
     (A18-1000GH)

7.  New Developments in the US Generics Regulatory requirements
     Dr Keith Webber, Deputy Director of Office of Generic Drugs, USFDA
     (A18-930KW)

8.  Making Medicines Affordable
     Douglas Andrews, on behalf of European Generics Association
     (A17-1645DA)

9.  Opportunities & Challenges for Chinese Manufacturers in the US generics Market
     Jonathan Embleton, COO, Amerigen Inc
     (A17-1645JE)

10.  The Role of China in Global Clinical Trials
        Dr Dingzhi Huang, Tianjin Medical University Cancer Institute
        (A18-900)

11.  Multinational and Chinese Pharma Companies jointly promote China Brand Generics in
        International Markets
        Dr Wu Xiaobin, Country Manager, Pfizer
        (A18-930 PF)

12.  The Chinese Pharmaceutical Industry approaches Europe - What are the alternatives
        Bruce Murdoch, Commercial Director, Stravencon and Asa Cox, Manager North America of Generics 2.0
        (A18-1000DA & A18-1000AC)

13.  Global quality Standards & Partnerships
        Tony Gould, Ex Programme Manager WHO
        (A18-1045 WHO)

14.  The Importance of Excipients in generic Drugs
        Liu Xiaoming, Huahai Pharma and Daniel Liu, Chairman of International Pharma Excipient
        Association of China
        (A18-1115LX and A18-1045DL)

15.  How a Major Indian Company went Global
        Dr Brian Tempest, Ex-CEO Ranbaxy Pharmaceuticals, India
        (A18-1000BT)

16.  IPR Protection for Pharmaceuticals
        Andreas Obst, IPR2 Key Expert
        (A18-1400AO)

17.  Generics & The Patent Landmine
        Karen Wong, Partner WSGR PC
        (A18-1430KW)

18.  Patent Dispute resolution relating to Generics
        Wenping Chen, King & Wood PRC
        (A18-1500WPC)